diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM10045diaendo-10045Research ArticleОбзорыReviewБиомаркеры диабетической ретинопатииBiomarkers for diabetic retinopathyhttps://orcid.org/0000-0002-5507-8775БудзинскаяМария ВикторовнаBudzinskayaMaria V.

д.м.н.

MD, PhD

m_budzinskaya@mail.ruhttps://orcid.org/0000-0002-2998-3392ЛипатовДмитрий ВалентиновичLipatovDmitry V.

д.м.н., проф.

MD, PhD, Professor

Glas1966@rambler.ruhttps://orcid.org/0000-0001-6744-4907ПавловВладислав ГеннадьевичPavlovVladislav G.

Аспирант отдела патологии сетчатки и зрительного нерва

MD

pavlovoculis@yandex.ruhttps://orcid.org/0000-0003-4757-5584ПетрачковДенис ВалериевичPetrachkovDenis V.

к.м.н. 

MD, PhD

petrachkov@doctor.comНаучно-исследовательский институт глазных болезнейРоссияResearch institute of eye diseasesRussian FederationНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology research centreRussian Federation2020210420202318894Copyright © Будзинская М.В., Липатов Д.В., Павлов В.Г., Петрачков Д.В., 20202020Будзинская М.В., Липатов Д.В., Павлов В.Г., Петрачков Д.В.Budzinskaya M.V., Lipatov D.V., Pavlov V.G., Petrachkov D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/10045

В статье проведен анализ современных публикаций по теме актуального в настоящее время направления биомедицины – исследования биомаркеров диабетической ретинопатии. Актуальность исследования обусловлена тем фактом, что выявление и идентификация биомаркеров каких-либо патологических процессов важны для скрининга, диагностики, мониторинга, профилактики и прогнозирования клинического ответа пациентов на проводимое лечение. Все это позволяет повысить эффективность и безопасность применения различных вариантов терапии, а следовательно, и улучшить отдаленный прогноз у пациентов с данным заболеванием.

В обзоре рассматриваются две основные группы биомаркеров (молекулярные и визуализируемые). Кроме того, приводится и анализируется современное состояние проблемы, рассматриваются перспективы изучения биомаркеров в контексте лечения диабетической ретинопатии. Очевидно, что поиск новых биомаркеров диабетической ретинопатии представляет важную и актуальную задачу не только для современной диабетологии, но и для эндокринологии в целом. Решение этого вопроса позволило бы перейти к выработке индивидуальных схем лечения этой патологии у пациентов с сахарным диабетом. Более тесное взаимодействие между офтальмологами и эндокринологами при лечении диабетической ретинопатии у пациентов привело бы к развитию персонализированной медицины в междисциплинарном аспекте.

A data analysis on the actual direction of biomedicine, the study of biomarkers in diabetic retinopathy (DR), was done. Biomarkers identification is important for screening, diagnosis, monitoring, prevention and prediction of the clinical response of the patient to the treatment. In addition, studying the biomarkers allows increase of the effectiveness and safety of using various treatment options. The review examines two main groups of biomarkers, molecular and visualised, which shows the current state of the problem and the prospects for studying biomarkers in the context of the DR treatment. Nowadays, searching for and finding new biomarkers is important and will allow us to develop individual treatment regimens for DR and personalised medicine in an interdisciplinary aspect: ophthalmology and endocrinology.

биомаркерысахарный диабетдиабетическая ретинопатиядиабетический макулярный отекперсонализированная медицинаbiomarkersdiabetes mellitusdiabetic retinopathydiabetic macular edemapersonalized medicineReferencesAronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharm. 2005;59(5):491–494. doi: https://doi.org/10.1111/J.1365-2125.2005.02435.XAronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharm. 2005;59(5):491–494. doi: https://doi.org/10.1111/J.1365-2125.2005.02435.XBiomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharm Ther. 2001;69(3):89–95. doi: https://doi.org/10.1067/Mcp.2001.113989Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharm Ther. 2001;69(3):89–95. doi: https://doi.org/10.1067/Mcp.2001.113989Мирошниченко И.И., Птицина С.Н. Биомаркеры в современной медико-биологической практике // Биомедицинская химия. — 2009. — Т. 55. — №4. — С. 425−440. [Miroshnichenko II, Ptitsyna SN. Biomarkers in the modern medical and biologic practice. Biomed khim. 2009;55(4):425−440. (In Russ.)]Мирошниченко И.И., Птицина С.Н. Биомаркеры в современной медико-биологической практике // Биомедицинская химия. — 2009. — Т. 55. — №4. — С. 425−440. [Miroshnichenko II, Ptitsyna SN. Biomarkers in the modern medical and biologic practice. Biomed khim. 2009;55(4):425−440. (In Russ.)]Waldman S, Terzic A. Targeted diagnostics and therapeutics for individualized patient management. Biomark Med. 2007;1(1):3–8. doi: https://doi.org/10.2217/17520363.1.1.3Waldman S, Terzic A. Targeted diagnostics and therapeutics for individualized patient management. Biomark Med. 2007;1(1):3–8. doi: https://doi.org/10.2217/17520363.1.1.3Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–287. doi: https://doi.org/10.1016/J.Trsl.2009.09.005Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–287. doi: https://doi.org/10.1016/J.Trsl.2009.09.005Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета // Сахарный диабет. — 2017. — T. 20. — №1. — C.13–41. [Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the Federal diabetes registry. Diabetes mellitus. 2017;20(1):13–41. (In Russ.)] doi: https://doi.org/10.14341/Dm8664Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета // Сахарный диабет. — 2017. — T. 20. — №1. — C.13–41. [Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the Federal diabetes registry. Diabetes mellitus. 2017;20(1):13–41. (In Russ.)] doi: https://doi.org/10.14341/Dm8664Федеральные клинические рекомендации: диагностика и лечение диабетической ретинопатии и диабетического макулярного отека. — М., 2013. [Federal clinical guidelines: diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Moscow; 2013. (In Russ.)] Доступно по: https://zodorov.ru/federalenie-klinicheskie-rekomendacii-diagnostika-i-lechenie-d.html. Ссылка активна на 12.11.2019.Федеральные клинические рекомендации: диагностика и лечение диабетической ретинопатии и диабетического макулярного отека. — М., 2013. [Federal clinical guidelines: diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Moscow; 2013. (In Russ.)] Доступно по: https://zodorov.ru/federalenie-klinicheskie-rekomendacii-diagnostika-i-lechenie-d.html. Ссылка активна на 12.11.2019.Липатов Д.В., Викулова О.К., Железнякова А.В., и др. Эпидемиология диабетической ретинопатии в Российской Федерации по данным Федерального регистра больных сахарным диабетом (2013–2016 гг.) // Сахарный диабет. — 2018. — Т. 21. — №4. — С. 230–240. [Lipatov DV, Vikulova OK, Zheleznyakova AV, et al. Trends in the epidemiology of diabetic retinopathy in Russian Federation according to the Federal diabetes register (2013–2016). Diabetes mellitus. 2018;21(4):230–240. (In Russ.)] doi: https://doi.org/10.14341/Dm9797Липатов Д.В., Викулова О.К., Железнякова А.В., и др. Эпидемиология диабетической ретинопатии в Российской Федерации по данным Федерального регистра больных сахарным диабетом (2013–2016 гг.) // Сахарный диабет. — 2018. — Т. 21. — №4. — С. 230–240. [Lipatov DV, Vikulova OK, Zheleznyakova AV, et al. Trends in the epidemiology of diabetic retinopathy in Russian Federation according to the Federal diabetes register (2013–2016). Diabetes mellitus. 2018;21(4):230–240. (In Russ.)] doi: https://doi.org/10.14341/Dm9797Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып // Сахарный диабет. — 2019. — Т. 22. — №1S1. — C. 1–144. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. (In Russ.)] doi: https://doi.org/10.14341/DM221S1Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып // Сахарный диабет. — 2019. — Т. 22. — №1S1. — C. 1–144. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. (In Russ.)] doi: https://doi.org/10.14341/DM221S1Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors ofdiabetic retinopathy. Diabetes care. 2012;35(3):556–564. doi: https://doi.org/10.2337/Dc11-1909Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors ofdiabetic retinopathy. Diabetes care. 2012;35(3):556–564. doi: https://doi.org/10.2337/Dc11-1909Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179–1187. doi: https://doi.org/10.1016/J.Oret.2018.06.004Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179–1187. doi: https://doi.org/10.1016/J.Oret.2018.06.004Iglicki M, Lavaque A, Ozimek M, et al. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: the vital study. Plos One 2018;13(7):e0200365. doi: https://doi.org/10.1371/Journal.Pone.0200365Iglicki M, Lavaque A, Ozimek M, et al. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: the vital study. Plos One 2018;13(7):e0200365. doi: https://doi.org/10.1371/Journal.Pone.0200365Borsey DQ, Prowse CV, Gray RS, et al. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol. 1984;37(6):659–664. doi: https://doi.org/10.1136/jcp.37.6.659Borsey DQ, Prowse CV, Gray RS, et al. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol. 1984;37(6):659–664. doi: https://doi.org/10.1136/jcp.37.6.659Madan R, Gupt B, Saluja S, et al. Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India. 2010;58:481–484.Madan R, Gupt B, Saluja S, et al. Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India. 2010;58:481–484.Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: a systematic review and meta-analysis. Ophthalmol. 2015;122(9):1820–1827. doi: https://doi.org/10.1016/J.Ophtha.2015.05.011Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: a systematic review and meta-analysis. Ophthalmol. 2015;122(9):1820–1827. doi: https://doi.org/10.1016/J.Ophtha.2015.05.011Singh RP, Habbu K, Ehlers JP, et al. The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmol. 2016;123(7):1581–1587. doi: https://doi.org/10.1016/J.Ophtha.2016.03.038Singh RP, Habbu K, Ehlers JP, et al. The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmol. 2016;123(7):1581–1587. doi: https://doi.org/10.1016/J.Ophtha.2016.03.038Астахов Ю.С., Залевская А.Г., Карпова И.А., и др. Факторы, влияющие на прогрессирование диабетической ретинопатии у больных сахарным диабетом 2-го типа после перевода на инсулинотерапию // РМЖ. Клиническая офтальмология. — 2005. — Т. 6. — №3. — С. 110–114. [Astakhov YuS, Zalevskaya AG, Karpova IA, et al. Factors, influencing diabetic retinopathy progression in type 2 diabetic patients after switching to insulin therapy. RMJ. Klinicheskaya oftal’mologiya. 2005;6(3):110–114. (In Russ.)]Астахов Ю.С., Залевская А.Г., Карпова И.А., и др. Факторы, влияющие на прогрессирование диабетической ретинопатии у больных сахарным диабетом 2-го типа после перевода на инсулинотерапию // РМЖ. Клиническая офтальмология. — 2005. — Т. 6. — №3. — С. 110–114. [Astakhov YuS, Zalevskaya AG, Karpova IA, et al. Factors, influencing diabetic retinopathy progression in type 2 diabetic patients after switching to insulin therapy. RMJ. Klinicheskaya oftal’mologiya. 2005;6(3):110–114. (In Russ.)]Funatsu H, Yamashita H, Ikeda T, et al. Angiotensin and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133(4):537–543. doi: https://doi.org/10.1016/s0002-9394(02)01323-5Funatsu H, Yamashita H, Ikeda T, et al. Angiotensin and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133(4):537–543. doi: https://doi.org/10.1016/s0002-9394(02)01323-5Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–2049. doi: https://doi.org/10.1056/nejmra0706596Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–2049. doi: https://doi.org/10.1056/nejmra0706596Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280(6):1358–1366. doi: https://doi.org/10.1152/ajpcell.2001.280.6.c1358Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280(6):1358–1366. doi: https://doi.org/10.1152/ajpcell.2001.280.6.c1358Борзилова Ю.А., Болдырева Л.А., Валеева Р.Р., и др. Уровень VEGF-а в слезной жидкости у пациентов с различными стадиями диабетической ретинопатии // Современные технологии в офтальмологии. — 2016. — №1. — С. 43–47. [Borzilova YuA, Boldyreva LA, Valeyeva RR, i dr. Uroven’ VEGF-a v sleznoy zhidkosti u patsiyentov s razlichnymi stadiyami diabeticheskoy retinopatii. Sovremennyye tekhnologii v oftal’mologii. 2016;(1):43–47. (In Russ.)]Борзилова Ю.А., Болдырева Л.А., Валеева Р.Р., и др. Уровень VEGF-а в слезной жидкости у пациентов с различными стадиями диабетической ретинопатии // Современные технологии в офтальмологии. — 2016. — №1. — С. 43–47. [Borzilova YuA, Boldyreva LA, Valeyeva RR, i dr. Uroven’ VEGF-a v sleznoy zhidkosti u patsiyentov s razlichnymi stadiyami diabeticheskoy retinopatii. Sovremennyye tekhnologii v oftal’mologii. 2016;(1):43–47. (In Russ.)]Homme RP, Singh M, Majumder A, et al. Remodeling of retinal architecture in diabetic retinopathy: disruption of ocular physiology and visual functions by inflammatory gene products and pyroptosis. Front Physiol. 2018;9:1268. doi: https://doi.org/10.3389/Fphys.2018.01268Homme RP, Singh M, Majumder A, et al. Remodeling of retinal architecture in diabetic retinopathy: disruption of ocular physiology and visual functions by inflammatory gene products and pyroptosis. Front Physiol. 2018;9:1268. doi: https://doi.org/10.3389/Fphys.2018.01268Кузьмин А.Г., Липатов Д.В., Смирнова О.М., Шестакова М.В. Анти-VEGF препараты для лечения диабетической ретинопатии // Офтальмохирургия. — 2009. — №3. — С. 53–57. [Kuz’min AG, Lipatov DV, Smirnova OM, Shestakova MV. Anti-VEGF preparaty dlya lecheniya diabeticheskoy retinopatii. Ophthalmosurgery. 2009;(3):53–57. (In Russ.)]Кузьмин А.Г., Липатов Д.В., Смирнова О.М., Шестакова М.В. Анти-VEGF препараты для лечения диабетической ретинопатии // Офтальмохирургия. — 2009. — №3. — С. 53–57. [Kuz’min AG, Lipatov DV, Smirnova OM, Shestakova MV. Anti-VEGF preparaty dlya lecheniya diabeticheskoy retinopatii. Ophthalmosurgery. 2009;(3):53–57. (In Russ.)]Dugel PU, Layton A, Varma R. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258–267. doi: https://doi.org/10.3928/23258160-20160229-09Dugel PU, Layton A, Varma R. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258–267. doi: https://doi.org/10.3928/23258160-20160229-09Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmol. 2009;116(1):73–79. doi: https://doi.org/10.1016/J.Ophtha.2008.09.037Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmol. 2009;116(1):73–79. doi: https://doi.org/10.1016/J.Ophtha.2008.09.037Kwon SH, Shin JP, Kim IT, Park DH. Aqueous levels of angiopoietin-like 4 and semaphorin 3e correlate with nonperfusion area and macular volume in diabetic retinopathy. Ophthalmol. 2015;122(5):968–975. doi: https://doi.org/10.1016/J.Ophtha.2015.01.007Kwon SH, Shin JP, Kim IT, Park DH. Aqueous levels of angiopoietin-like 4 and semaphorin 3e correlate with nonperfusion area and macular volume in diabetic retinopathy. Ophthalmol. 2015;122(5):968–975. doi: https://doi.org/10.1016/J.Ophtha.2015.01.007Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4). pii: E942. doi: https://doi.org/10.3390/ijms19040942Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4). pii: E942. doi: https://doi.org/10.3390/ijms19040942Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis. Prog Retin Eye Res. 2017;60:44–65. doi: https://doi.org/10.1016/j.preteyeres.2017.08.001Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis. Prog Retin Eye Res. 2017;60:44–65. doi: https://doi.org/10.1016/j.preteyeres.2017.08.001Di Carlo SE, Peduto L. The perivascular origin of pathological fibroblasts. J Clin Invest. 2018;128(1):54–63. doi: https://doi.org/10.1172/JCI93558Di Carlo SE, Peduto L. The perivascular origin of pathological fibroblasts. J Clin Invest. 2018;128(1):54–63. doi: https://doi.org/10.1172/JCI93558Arevalo JF, Maia M, Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–216. doi: https://doi.org/10.1136/bjo.2007.127142Arevalo JF, Maia M, Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–216. doi: https://doi.org/10.1136/bjo.2007.127142Pang JP, Son G, Yoon YH, et al. Combined vitrectomy with intravitreal dexamethasone implant for refractory macular edema secondary to diabetic retinopathy, retinal vein occlusion, and noninfectious posterior uveitis. Retina. 2020;40(1):56–65. doi: https://doi.org/10.1097/Iae.0000000000002358Pang JP, Son G, Yoon YH, et al. Combined vitrectomy with intravitreal dexamethasone implant for refractory macular edema secondary to diabetic retinopathy, retinal vein occlusion, and noninfectious posterior uveitis. Retina. 2020;40(1):56–65. doi: https://doi.org/10.1097/Iae.0000000000002358Choi JA, Ko SH, Park YR, et al. Retinal nerve fiber layer loss is associated with urinary albumin excretion in patients with type 2 diabetes. Ophthalmol. 2015;122(5):976–981. doi: https://doi.org/10.1016/J.Ophtha.2015.01.001Choi JA, Ko SH, Park YR, et al. Retinal nerve fiber layer loss is associated with urinary albumin excretion in patients with type 2 diabetes. Ophthalmol. 2015;122(5):976–981. doi: https://doi.org/10.1016/J.Ophtha.2015.01.001Wang H, Chhablani J, Freeman WR, et al. Characterization of diabetic microaneurysms by simultaneous fluorescein angiography and spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;153(5):861–867.e1. doi: https://doi.org/10.1016/j.ajo.2011.10.005Wang H, Chhablani J, Freeman WR, et al. Characterization of diabetic microaneurysms by simultaneous fluorescein angiography and spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;153(5):861–867.e1. doi: https://doi.org/10.1016/j.ajo.2011.10.005Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmol. 1991;98(5 Suppl):766–785. doi: https://doi.org/10.1016/s0161-6420(13)38011-7Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmol. 1991;98(5 Suppl):766–785. doi: https://doi.org/10.1016/s0161-6420(13)38011-7Silva PS, Cavallerano JD, Haddad NM, et al. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmol. 2015;122(5):949–956. doi: https://doi.org/10.1016/J.Ophtha.2015.01.008Silva PS, Cavallerano JD, Haddad NM, et al. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmol. 2015;122(5):949–956. doi: https://doi.org/10.1016/J.Ophtha.2015.01.008Witmer MT, Kiss S. The clinical utility of ultra-wide-field imaging [Internet]. Rev Ophthalmol. [cited 2012 March 8] Available from: https://www.reviewofophthalmology.com/article/the-clinical-utility-of-ultra-wide-field-imagingWitmer MT, Kiss S. The clinical utility of ultra-wide-field imaging [Internet]. Rev Ophthalmol. [cited 2012 March 8] Available from: https://www.reviewofophthalmology.com/article/the-clinical-utility-of-ultra-wide-field-imagingSilva PS, El-Rami H, Barham R, et al. Hemorrhage and/or microaneurysm severity and count in ultrawide field images and early treatment diabetic retinopathy study photography. Ophthalmol 2017;124(7):970–976. doi: https://doi.org/10.1016/J.Ophtha.2017.02.012Silva PS, El-Rami H, Barham R, et al. Hemorrhage and/or microaneurysm severity and count in ultrawide field images and early treatment diabetic retinopathy study photography. Ophthalmol 2017;124(7):970–976. doi: https://doi.org/10.1016/J.Ophtha.2017.02.012Shah VP, Shah SA, Mrejen S, Freund KB. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina. 2014;34(7):1281–12888. doi: https://doi.org/10.1097/IAE.0000000000000166Shah VP, Shah SA, Mrejen S, Freund KB. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina. 2014;34(7):1281–12888. doi: https://doi.org/10.1097/IAE.0000000000000166Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema. Retina. 2019;39(1):88–97. doi: https://doi.org/10.1097/Iae.0000000000002110Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema. Retina. 2019;39(1):88–97. doi: https://doi.org/10.1097/Iae.0000000000002110Santos A, Costa M, Schwartz C, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema. Retina. 2018;38(6):1110–1119. doi: https://doi.org/10.1097/IAE.0000000000001687Santos A, Costa M, Schwartz C, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema. Retina. 2018;38(6):1110–1119. doi: https://doi.org/10.1097/IAE.0000000000001687Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132(11):1309–1316. doi: https://doi.org/10.1001/Jamaophthalmol.2014.2350Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132(11):1309–1316. doi: https://doi.org/10.1001/Jamaophthalmol.2014.2350Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmol. 2015;122(7):1395–1401. doi: https://doi.org/10.1016/J.Ophtha.2015.02.036Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmol. 2015;122(7):1395–1401. doi: https://doi.org/10.1016/J.Ophtha.2015.02.036Santos AR, Alves D, Santos T, et al. Measurements of retinal fluid by optical coherence tomography leakage in diabetic macular edema. Retina. 2019;39(1):52–60. doi: https://doi.org/10.1097/Iae.0000000000001905Santos AR, Alves D, Santos T, et al. Measurements of retinal fluid by optical coherence tomography leakage in diabetic macular edema. Retina. 2019;39(1):52–60. doi: https://doi.org/10.1097/Iae.0000000000001905Moein HR, Novais EA, Rebhun CB, et al. Optical coherence tomography angiography to detect macular capillary ischemia in patients with inner retinal changes after resolved diabetic macular edema. Retina. 2018;38(12):2277–2284. doi: https://doi.org/10.1097/Iae.0000000000001902Moein HR, Novais EA, Rebhun CB, et al. Optical coherence tomography angiography to detect macular capillary ischemia in patients with inner retinal changes after resolved diabetic macular edema. Retina. 2018;38(12):2277–2284. doi: https://doi.org/10.1097/Iae.0000000000001902Regatieri CV, Branchini L, Carmody J, et al. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina. 2012;32(3):563–568. doi: https://doi.org/10.1097/Iae.0b013e31822f5678Regatieri CV, Branchini L, Carmody J, et al. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina. 2012;32(3):563–568. doi: https://doi.org/10.1097/Iae.0b013e31822f5678Niestrata-Ortiz M, Fichna P, Stankiewicz W, Stopa M. Determining the effect of diabetes duration on retinal and choroidal thicknesses in children with type 1 diabetes mellitus. Retina. 2020;40(3):421–427. doi: https://doi.org/10.1097/Iae.0000000000002420Niestrata-Ortiz M, Fichna P, Stankiewicz W, Stopa M. Determining the effect of diabetes duration on retinal and choroidal thicknesses in children with type 1 diabetes mellitus. Retina. 2020;40(3):421–427. doi: https://doi.org/10.1097/Iae.0000000000002420Kang HM, Lee NE, Choi JH, et al. Significant reduction of both peripapillary and subfoveal choroidal thickness after panretinal photocoagulationin patients with type 2 diabetes. Retina. 2018;38(10):1905–1912. doi: https://doi.org/10.1097/Iae.0000000000001804Kang HM, Lee NE, Choi JH, et al. Significant reduction of both peripapillary and subfoveal choroidal thickness after panretinal photocoagulationin patients with type 2 diabetes. Retina. 2018;38(10):1905–1912. doi: https://doi.org/10.1097/Iae.0000000000001804Coscas G, De Benedetto U, Coscas F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica. 2013;229(1):32–37. doi: https://doi.org/10.1159/000342159Coscas G, De Benedetto U, Coscas F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica. 2013;229(1):32–37. doi: https://doi.org/10.1159/000342159Vujosevic S, Bini S, Torresin T, et al. Hyperreflective retinal spots innormal and diabetic eyes: b-scan and en face spectral domain optical coherence tomography evaluation. Retina. 2017;37(6):1092–1103. doi: https://doi.org/10.1097/Iae.0000000000001304Vujosevic S, Bini S, Torresin T, et al. Hyperreflective retinal spots innormal and diabetic eyes: b-scan and en face spectral domain optical coherence tomography evaluation. Retina. 2017;37(6):1092–1103. doi: https://doi.org/10.1097/Iae.0000000000001304Chen KC, Jung JJ, Curcio CA, el al. Intraretinal hyperreflective foci in acquired vilelliform lesions of the macula: clinical and histologic study. Am J Ophthalmol. 2016;164:89–98. doi: https://doi.org/10.1016/j.ajo.2016.02.002Chen KC, Jung JJ, Curcio CA, el al. Intraretinal hyperreflective foci in acquired vilelliform lesions of the macula: clinical and histologic study. Am J Ophthalmol. 2016;164:89–98. doi: https://doi.org/10.1016/j.ajo.2016.02.002Zanzottera EC, Messinger JD, Ach T, et al. The project macula retinal pigment epithelium grading system for histology and optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56(5):3253–3268. doi: https://doi.org/10.1167/iovs.15-16431Zanzottera EC, Messinger JD, Ach T, et al. The project macula retinal pigment epithelium grading system for histology and optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56(5):3253–3268. doi: https://doi.org/10.1167/iovs.15-16431Pang CE, Messinger JD, Zanzottera EC, et al. The onion sign in neovascular age-related macular degeneration represents cholesterol crystals. Ophthalmol. 2015;122(11):2316–2326. doi: https://doi.org/10.1016/j.ophtha.2015.07.008Pang CE, Messinger JD, Zanzottera EC, et al. The onion sign in neovascular age-related macular degeneration represents cholesterol crystals. Ophthalmol. 2015;122(11):2316–2326. doi: https://doi.org/10.1016/j.ophtha.2015.07.008Sadiq MA, Soliman MK, Sarwar S, et al. Effect of vitreomacular adhesion on treatment outcomes in the ranibizumab for edema of the macula in diabetes (read-3) study. Ophthalmol. 2016;123(2):324–329. doi: https://doi.org/10.1016/J.Ophtha.2015.09.032Sadiq MA, Soliman MK, Sarwar S, et al. Effect of vitreomacular adhesion on treatment outcomes in the ranibizumab for edema of the macula in diabetes (read-3) study. Ophthalmol. 2016;123(2):324–329. doi: https://doi.org/10.1016/J.Ophtha.2015.09.032Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmol. 2015;122(2):367–374. doi: https://doi.org/10.1016/J.Ophtha.2014.08.048Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmol. 2015;122(2):367–374. doi: https://doi.org/10.1016/J.Ophtha.2014.08.048Zur D, Iglicki M, Busch C, et al. Optical coherence tomography biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmol. 2018;125(2):267–275. doi: https://doi.org/10.1016/J.Ophtha.2017.08.031Zur D, Iglicki M, Busch C, et al. Optical coherence tomography biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmol. 2018;125(2):267–275. doi: https://doi.org/10.1016/J.Ophtha.2017.08.031Kim JH, Lee MW, Byeon SH, et al. Associations between individual retinal layer thicknesses and diabetic peripheral neuropathy using retinal layer segmentation analysis. Retina. 2018;38(11):2190–2196. doi: https://doi.org/10.1097/Iae.0000000000001835Kim JH, Lee MW, Byeon SH, et al. Associations between individual retinal layer thicknesses and diabetic peripheral neuropathy using retinal layer segmentation analysis. Retina. 2018;38(11):2190–2196. doi: https://doi.org/10.1097/Iae.0000000000001835Ho J, Dans K, You Q, et al. Comparison of 3 mm × 3 mm versus 6 mm × 6 mm optical coherence tomography angiography scan sizes in the evaluation of non-proliferative diabetic retinopathy. Retina. 2019;39(2):259–264. doi: https://doi.org/10.1097/Iae.0000000000001951Ho J, Dans K, You Q, et al. Comparison of 3 mm × 3 mm versus 6 mm × 6 mm optical coherence tomography angiography scan sizes in the evaluation of non-proliferative diabetic retinopathy. Retina. 2019;39(2):259–264. doi: https://doi.org/10.1097/Iae.0000000000001951Alibhai AY, De Pretto LR, Moult EM, et al. Quantification of retinal capillary nonperfusion in diabetics using wide-field optical coherence tomography angiography. Retina. 2020;40(3):412–420. doi: https://doi.org/10.1097/Iae.0000000000002403Alibhai AY, De Pretto LR, Moult EM, et al. Quantification of retinal capillary nonperfusion in diabetics using wide-field optical coherence tomography angiography. Retina. 2020;40(3):412–420. doi: https://doi.org/10.1097/Iae.0000000000002403Alam M, Zhang Y, Lim JI, et al. Quantitative optical coherence tomography angiography features for objective classification and staging of diabetic retinopathy. Retina. 2018. doi: https://doi.org/10.1097/Iae.0000000000002373Alam M, Zhang Y, Lim JI, et al. Quantitative optical coherence tomography angiography features for objective classification and staging of diabetic retinopathy. Retina. 2018. doi: https://doi.org/10.1097/Iae.0000000000002373Lee J, Moon BG, Cho AR, et al. Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. Ophthalmology. 2016;123(11):2368–2375. doi: https://doi.org/10.1016/j.ophtha.2016.07.010Lee J, Moon BG, Cho AR, et al. Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. Ophthalmology. 2016;123(11):2368–2375. doi: https://doi.org/10.1016/j.ophtha.2016.07.010

The authors declare that there are no conflicts of interest present.